Illumina will appeal, following the European decision on Grail

(Boursier.com) — Illuminated , a US life sciences giant, is set to divest from biotech firm Grail after the European Commission banned the $7.1 billion takeover on the pretext that the deal would harm competition in the market for cancer detection tests . Illumina intends to appeal. The group had completed the deal in August last year before the agreement of the European antitrust regulator. The EU had then ordered to keep the activity separate until the conclusion of the European investigation. The “in-depth” investigation confirmed initial concerns, the Commission says, finding that Illumina would then display a dominant position in NGS systems, with the ability to thwart rivals.